CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that on October 1, 2025, it granted equity awards to 27 new non-executive employees as inducement grants under the company’s 2025 Inducement Plan. The awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants, intended to attract and retain key talent, include options to purchase a total of 1,602 shares of common stock and 10,973 time-based restricted stock units. The options have an exercise price of $449.14 per share — the closing price of Madrigal’s common stock on the grant date.
Under the terms of the plan, 25% of the stock options will vest on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments over the following three years. The restricted stock units will vest in four equal installments on each of the first through fourth anniversaries of the grant date, contingent upon continued employment.
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease with limited treatment options. Its lead therapy, Rezdiffra (resmetirom), is the first and only medication approved by both the U.S. Food and Drug Administration and the European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3).
The company is also conducting a Phase 3 outcomes trial evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c), as it continues to advance therapies addressing serious liver and metabolic diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.